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Abstract 
Background: Patients with type 1 diabetes (T1D) are at increased risk of cardiovascular disease (CVD). Measures of 
high‑density lipoprotein (HDL) function provide a better risk estimate for future CVD events than serum levels of HDL 
cholesterol. The objective of this study was to evaluate HDL function in T1D patients shortly after disease onset com‑
pared with healthy control subjects.
Methods: Participants in the atherosclerosis and childhood diabetes study were examined at baseline and after 
5 years. At baseline, the cohort included 293 T1D patients with a mean age of 13.7 years and mean HbA1c of 8.4%, 
along with 111 healthy control subjects. Their HDL function, quantified by HDL‑apoA‑I exchange (HAE), was assessed 
at both time points. HAE is a measure of HDL’s dynamic property, specifically its ability to release lipid‑poor apolipo‑
protein A‑I (apoA‑I), an essential step in reverse cholesterol transport.
Results: The HAE‑apoA‑I ratio, reflecting the HDL function per concentration unit apoA‑I, was significantly lower in 
the diabetes group both at baseline, 0.33 (SD = 0.06) versus 0.36 (SD = 0.06) %HAE/mg/dL, p < 0.001 and at follow‑
up, 0.34 (SD = 0.06) versus 0.36 (SD = 0.06)  %HAE/mg/dL, p = 0.003. HAE‑apoA‑I ratio was significantly and inversely 
correlated with HbA1c in the diabetes group. Over the 5 years of the study, the mean HAE‑apoA‑I ratio remained 
consistent in both groups. Individual changes were less than 15% for half of the study participants.
Conclusions: This study shows reduced HDL function, quantified as HAE‑apoA‑I ratio, in children and young adults 
with T1D compared with healthy control subjects. The differences in HDL function appeared shortly after disease 
onset and persisted over time.
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Background
Patients with type 1 diabetes (T1D) are at an increased 
risk of morbidity and mortality from cardiovascular dis-
ease (CVD) [1, 2]. The underlying mechanisms are only 
partly understood and even when traditional risk factors 
for CVD have been addressed, patients with diabetes 
bear significant residual risk for CVD [3].
In clinical studies high-density lipoprotein cholesterol 
(HDL-C) levels are consistently inversely associated 
with coronary heart disease events and mortality [4, 5]. 
Despite the overall inverse association of HDL-C with 
CVD risk, nearly 40% of men with coronary heart disease 
have normal HDL-C levels [6], and very high HDL-C lev-
els are associated with increased risk for major coronary 
events [7]. Thus, HDL-C levels alone do not provide a 
complete explanation for the atheroprotective effects of 
HDL, suggesting that not all HDL are functionally equiv-
alent, and that the cardioprotective nature of HDL is 
not accurately represented by circulating HDL-C levels. 
Consequently, the focus has shifted to measures of HDL 
function, which have yielded a better assessment of CVD 
risk than HDL-C quantification [8, 9].
The cell-based measure of serum cholesterol efflux 
capacity (CEC) is the “gold standard” method to assess 
the efficiency of an individual’s HDL to facilitate reverse 
cholesterol transport (RCT) [10], a process by which 
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cholesterol is removed from lipid-laden macrophages and 
delivered primarily to the liver and steroidogenic organs. 
Clinical studies have demonstrated a strong inverse rela-
tionship between CEC and prevalent and incident CVD 
[11–13]. Recently, a study of 1972 patients in the Dallas 
Heart Study reported significantly improved atheroscle-
rotic CVD risk assessment when adding CEC to family 
history, coronary calcium score and C-reactive protein 
[9]. These studies demonstrate the importance of includ-
ing CEC in determining cardiovascular risk-prediction 
indexes. However, since the CEC assay is cell-based, 
it is difficult to standardize and apply on an individual 
basis. Furthermore, hypertriglyceridemia has been impli-
cated in yielding artifactually elevated measures of CEC 
[14]. Combined, these issues complicate the CEC assay’s 
implementation in a high throughput clinical diagnostic 
laboratory [8].
Apolipoprotein A-I (apoA-I), the main protein compo-
nent of HDL, is an important mediator of RCT by pro-
moting lipid efflux via membrane-bound ATP-binding 
cassette transporter A1 (ABCA1) [15, 16]. The ability 
of HDL to release lipid-poor apoA-I, the primary sub-
strate for de novo HDL biogenesis via ABCA1, has 
been hypothesized as the rate-limiting step of RCT 
(Fig.  1) [17]. ApoA-I undergoes significant conforma-
tional change upon association/dissociation with HDL, 
and this transition can be quantified by electron para-
magnetic resonance (EPR) or fluorescent methods as a 
measure of HDL-apoA-I exchange (HAE) [18–20]. HAE 
is a discriminating measure of HDL function, distin-
guishing healthy from CVD states in both animals and 
humans [18]. Furthermore, HAE strongly correlates with 
the CEC assay (r = 0.69, p < 0.001) in subjects with nor-
molipidemic profiles [21]. HAE calculated per unit HDL, 
as the HAE-apoA-I ratio, yields a measure of HDL func-
tion analogous to enzymatic specific activity and is more 
discriminating of CVD status than HAE alone [21].
We hypothesized that residual CVD risk in diabetes 
patients is at least in part derived from early onset and 
sustained HDL dysfunction in these individuals. To test 
this hypothesis, we quantified HDL function by the HAE 
assay in children and young adults with T1D.
Fig. 1 Cholesterol transport in the intima and measurements of HDL function. To facilitate cholesterol efflux from cholesterol‑laden macrophages 
(MΦ), lipid‑poor apoA‑I binds to ABCA1. During its association with ABCA1, apoA‑I acquires free cholesterol (FC) and phospholipid (PL) to form 
discoidal alpha HDL (red arrow). These particles are acted upon by LCAT and converted to cholesterol ester core containing alpha HDL. ApoA‑I is lib‑
erated from alpha HDL by the action(s) of phospholipid transfer protein (PLTP), cholesterol ester transfer protein (CETP), lipoprotein lipase (LPL) and 
hepatic lipase (HL) to generate lipid‑poor apoA‑I and preβ HDL (green arrows). The formation of lipid‑poor apoA‑I and preβ by HDL is a rate‑limiting 
step of this process. These processes can be quantified by the CEC (red arrow) and HAE (green arrows) assays
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Methods
Study population
The atherosclerosis and childhood diabetes (ACD) study 
started in 2006, and included 314 children and adoles-
cents with T1D along with 120 healthy control subjects. 
They were 8–18 years old and resided in the South East 
health region of Norway. The inclusion process and 
details of the cohort have been described previously 
[22, 23]. From 2011 to 2013, a 5-year follow-up was con-
ducted, and 80% of the original participants were exam-
ined along with 38 newly recruited control subjects. The 
HAE assay was performed on serum samples from 293 
patients and 111 control subjects at baseline and 241 
patients and 128 control subjects at follow-up.
Written informed consent was directly provided by 
participants over 18 years of age and by at least one par-
ent for participants less than 18 years of age. The proto-
cols at baseline and follow-up have both been approved 
by the Norwegian Regional Committee for Medical and 
Health Research Ethics. The study was conducted accord-
ing to the Declaration of Helsinki.
Clinical and laboratory methods
All blood samples were drawn in the morning between 
08:00 and 10:00 am after an overnight fast, centrifuged 
within 1  h at 2500×g for 10  min and stored at −80  °C 
until analysis.
ApoA-I levels were determined by immunoturbidim-
etry (Roche Diagnostics, Basel, Switzerland), and the 
coefficient of variation (CV) was 4%. C-reactive protein 
(CRP) was measured by high sensitivity ELISA (DRG 
Instruments GmbH, Germany) with a detection limit 
of 0.1  mg/L. The inter-assay CV was  <5%. HbA1c was 
analyzed at a DCCT-standardized laboratory by high 
performance liquid chromatography (Variant; Bio-Rad, 
Richmond, CA, USA), CV <3%. Other routine laboratory 
analyses were performed by conventional methods.
HAE assay
Freshly thawed plasma was treated with polyethylene 
glycol to precipitate apoB-containing lipoproteins and 
mixed with 3 mg/mL nitroxide spin-labeled apoA-I probe 
[18]. EPR was performed using a Bruker eScan EPR spec-
trometer (Bruker BioSpin GmbH, Karlsruhe, Germany) 
outfitted with a temperature controller (Noxygen Science 
Transfer & Diagnostics GmbH, Elzach, Germany). Sam-
ples were incubated for 15 min at 37  °C and scanned at 
37  °C. The peak amplitude of the nitroxide signal from 
HAE probe in the sample (3462–3470 Gauss) was com-
pared to the peak amplitude of a proprietary internal 
standard (3507–3515 Gauss) provided by Bruker. The 
internal standard is contained within the eScan spec-
trometer cavity and does not contact the sample. Since 
the y-axis of an EPR spectrum is measured in arbitrary 
units, measuring the sample against a fixed internal 
standard facilitates normalization of sample response. 
HAE activity represents the sample: internal standard 
signal ratio at 37 °C. The maximal %HAE activity was cal-
culated by comparing HAE activity to a standard curve 
ranging in the degree of probe lipid-associated signal. All 
samples were read in duplicate and averaged. The final 
result reflects the relative efficiency of apoA-I exchange. 
Intra-assay CV was 4%.
Carotid intima‑media thickness
At baseline, carotid intima-media thickness (cIMT) of the 
common carotid arteries was acquired using a Siemens 
Acuson Sequoia 512 ultrasound scanner (Siemens Acu-
son; Mountain View, CA, USA) equipped with a linear 
array 14 MHz transducer. Further details of the examina-
tion have been described previously [22]. At follow-up, 
cIMT was determined using a Zonare Z-one Ultra ultra-
sound scanner (Zonare Medical Systems; Mountain View, 
CA, USA) equipped with a linear array 8 MHz transducer 
and analyzed using M’Ath 3.2.0. software (Intelligence in 
Medical Imaging; Paris, France). All cIMT measurements 
were from the far wall of the common carotid arteries in 
end-diastole. When calculating Young’s modulus, blood 
pressure values recorded by a standard oscillometric 
device over the brachial artery were used.
Statistical analysis
Demographic and clinical data are presented as either 
means with standard deviations (SD), medians with 25th 
and 75th percentiles or proportions. Student’s t test, or 
Mann–Whitney U test in case of non-normally distrib-
uted data, was applied to test differences in continuous 
variables between groups. Pearson’s correlation coeffi-
cient (r), or Spearman’s rho (ρ) in case of non-normally 
distributed data, was applied for correlation analyses 
between continuous variables. Univariate regression 
analysis was performed to identify associations between 
HAE-apoA-I ratio as an exposure variable and surrogate 
markers of atherosclerosis as outcome variables, as well 
as associations between HAE-apoA-I ratio, gender and 
HbA1c. Multivariate regression analysis with a backward 
elimination procedure was performed to determine and 
control for confounding variables. For model inclusion, 
these variables were required to be associated with both 
the exposure and outcome variables with p < 0.05. Mul-
tivariate regression analysis with a backward elimination 
procedure was also applied to identify risk factors for 
HAE-apoA-I ratio. Variables with a p value  <0.20 from 
univariate analysis were considered as candidates for 
the multivariate model. In all analyses, statistical signifi-
cance was assumed for p < 0.05. The software IBM SPSS 
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Statistics for Macintosh, version 19.0 (Armonk, NY: IBM 
Corp.) was used for all statistical analyses.
Results
The clinical and metabolic characteristics of the diabetes 
patients and the healthy control subjects are presented 
in Table  1. The diabetes patients had higher diastolic 
blood pressure, HbA1c, total cholesterol, LDL cho-
lesterol, apoB, apoA-I, body weight, body mass index 
(BMI) and waist circumference compared with controls 
both at baseline and at the 5-year follow-up. At baseline, 
when compared with the Norwegian Childhood Diabe-
tes Registry, the cohort was a representative sample of 
the young T1D population in Norway regarding HbA1c, 
blood pressure, lipid status as well as gender and stage of 
puberty [22]. Since patients under 8 years of age were not 
included, the subjects of this study had diagnosed diabe-
tes for a longer period, had higher BMI, were more fre-
quently insulin pump users and were slightly older than 
the total population of youth with T1D in Norway.
The HAE-apoA-I ratio, a measure of HDL function 
per concentration unit of apoA-I (g/L), was significantly 
lower in the diabetes group compared with the controls 
both at baseline and at follow-up (Table 1). The relation-
ship between HAE and apoA-I at baseline is illustrated in 
Fig. 2.
The mean HAE-apoA-I ratio for the entire cohort was 
stable over the 5 years studied (Table 1). In order to eval-
uate change over time on an individual level, delta vari-
ables were created. Values for the delta variables were 
concentrated around zero, as exemplified by the fre-
quency distribution for delta HAE-apoA-I ratio among 
diabetes patients (Fig.  3). Furthermore, the standard 
deviation was 0.08%/mg/dL and the interquartile range 
was 0.10%/mg/dL in both groups, demonstrating that the 
individual change in HAE-apoA-I ratio over 5 years was 
less than 15% for half of the participants.
At baseline, there was no significant gender differ-
ence in HAE-apoA-I ratio in either the diabetes group 
or in the control group. At the 5-year follow-up, how-
ever, females had significantly lower HAE-apoA-I ratio 
than males both in the diabetes group, 0.35 (SD = 0.06) 
versus 0.33 (SD = 0.05) %/mg/dL, p = 0.041, and in the 
control group, 0.37 (SD = 0.06) versus 0.35 (SD = 0.05) 
%/mg/dL, p  =  0.047. The association between female 
gender and HAE-apoA-I ratio remained significant in a 
Table 1 Clinical and metabolic characteristics at baseline and follow-up
Mean values (SD)
HAE HDL-apoA-I exchange
a Median (25th and 75th percentile)
Baseline 5‑year follow‑up
Diabetes Controls p value Diabetes Controls p value
n 293 111 241 128
Diabetes duration (years) 5.6 (3.4) 10.3 (3.6)
Insulin pump users (%) 52.9 61.3
Age (years) 13.7 (2.8) 13.3 (2.5) 0.175 18.7 (2.8) 18.7 (2.9) 0.895
Girls, n (%) 147 (50.2) 63 (56.8) 0.265 129 (53.5) 72 (56.3) 0.661
Height (cm) 160.4 (14.5) 157.6 (13.3) 0.072 171.2 (9.1) 172.1 (9.2) 0.383
Weight (kg) 54.8 (16.8) 48.4 (13.2) <0.001 71.0 (14.6) 66.9 (12.5) 0.006
BMI (kg/m2) 20.8 (4.0) 19.1 (3.1) <0.001 24.1 (4.3) 22.5 (3.4) <0.001
Waist circumference (cm) 71.2 (10.0) 66.8 (6.6) <0.001 79.0 (9.6) 75.5 (8.2) < 0.001
Systolic blood pressure (mmHg) 101 (10) 98 (10) 0.018 112 (11) 111 (10) 0.656
Diastolic blood pressure (mmHg) 60 (8) 58 (7) 0.018 70 (8) 68 (8) 0.024
HbA1c (%) (mmol/mol, SD) 8.4 (1.3) [68, 13] 5.3 (0.3) [34, 3] <0.001 9.0 (1.4) [75, 15] 5.2 (0.3) [3, 33] <0.001
Total Cholesterol (mg/dL) 178 (31) 166 (27) 0.001 186 (39) 170 (39) 0.001
HDL (mg/dL) 70 (15) 66 (15) 0.065 62 (19) 62 (15) 0.161
LDL (mg/dL) 97 (27) 89 (27) 0.016 104 (31) 97 (31) 0.014
Triglycerides (mg/dL)a 62 (44, 80) 62 (44, 80) 0.457 80 (53, 115) 71 (53, 89) 0.024
Apolipoprotein B (mg/dL) 74 (19) 66 (17) <0.001 90 (26) 79 (23) <0.001
Apolipoprotein A‑I (mg/dL) 154 (28) 147 (27) 0.026 156 (31) 148 (27) 0.006
Urine albumin/creatinine (mg/mmol)a 6.2 (3.5, 11.5) 5.7 (3.3, 12.0) 0.637 5.8 (2.7, 13.7) 3.0 (1.7, 8.0) 0.001
HDL‑apoA‑1 exchange (%) 50.7 (9.8) 52.4 (9.2) 0.105 52.1 (10.4) 52.1 (10.2) 0.960
HAE‑apoA‑1 ratio (%/mg/dL) 0.33 (0.06) 0.36 (0.06) <0.001 0.34 (0.06) 0.36 (0.06) 0.003
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linear regression model controlling for pubertal stage. 
In the diabetes group at the 5-year follow-up, females 
taking oral contraceptives had significantly lower HAE-
apoA-I ratio than females not taking oral contracep-
tives, 0.34 (SD = 0.05) versus 0.32 (SD = 0.05) %/mg/dL, 
p = 0.019. There was no difference in the control group. 
Diabetic females using oral contraceptives also had sig-
nificantly lower HAE-apoA-I ratio than diabetic males, 
0.35 (SD  =  0.06) versus 0.32 (SD  =  0.05) %/mg/dL, 
p  =  0.002. There was no significant difference between 
diabetic females not taking oral contraceptives and dia-
betic males. Among males at the 5-year follow-up, the 
diabetes patients had significantly lower HAE-apoA-I 
ratio than control subjects, 0.37 (SD = 0.06) versus 0.35 
(SD = 0.06) %/mg/dL, p = 0.029.
The HAE-apoA-I ratio was significantly and inversely 
correlated with HbA1c, except in the control group at 
baseline, as shown in Table 2.
In linear multiple regression analyses (Table  3), the 
association between HAE-apoA-I ratio and HbA1c in 
the diabetes group at baseline remained significant, 
B = −0.707, p =  0.007 and  R2 =  0.094, controlling for 
total cholesterol levels. In the diabetes group at follow-
up, the association was confounded by smoking and total 
cholesterol levels. In the control group at follow-up, the 
association remained significant, B = −5.508, p = 0.002 
and  R2 = 0.078, no confounding variables.
Predictive linear regression models to determine risk 
factors for HDL function were generated for each group 
(Table 4). In the diabetes group at baseline, insulin pump 
use, total cholesterol, HDL cholesterol and HbA1c were 
significant,  R2  =  0.151 for the model. At follow-up, 
smoking, HbA1c and HDL cholesterol were significant, 
 R2 = 0.108. In the control group the significant risk fac-
tors were smoking, and HDL cholesterol at baseline, 
 R2 =  0.104, and HDL cholesterol and HbA1c at follow-
up,  R2 = 0.176.
There were no significant associations between HDL 
function and either cIMT, Young’s modulus or CRP at 
either time point.
Discussion
In this study, HDL function, as measured by HAE-apoA-
I ratio, was reduced in patients with childhood onset 
T1D in comparison with healthy control subjects. The 
difference was observed in patients with a mean age of 
13.7 years at baseline, and was still present at a follow-up 
examination 5 years later. This is the first study to exam-
ine HAE in a cohort of youth with T1D. Importantly, we 
demonstrate for the first time that changes in HAE are 
a sustained effect that occur early in the onset of T1D. 
HAE is a key aspect of RCT, consequently, these results 
indicate that reduction in HDL function may be a mecha-
nism underlying the increased risk of CVD seen in T1D. 
Fig. 2 The relationship between  %HAE and apoA‑I at baseline. 
N = 293 T1D patients. N = 111 for healthy control subjects. All 
resided in the South East region of Norway and had a mean age of 
13.7 years. The average  %HAE for the T1D subjects was 50.7 and 52.4 
for controls. T1D subjects differed significantly from healthy controls 
in %HAE‑apoA‑I (p < 0.001)
Fig. 3 Frequency distribution for delta HAE‑apoA‑1 ratio in diabetes 
patients. The delta value is calculated by subtracting the baseline 
value from the follow‑up value of HAE‑apoA‑I ratio for each partici‑
pant. N = 218. The values for most patients are close to zero, indicat‑
ing little change in HAE‑apoA‑I ratio over the 5 years of the study
Table 2 Correlations between HAE-apoA-I ratio and HbA1c 
at baseline and follow-up
Baseline 5‑year follow‑up
Pearson’s r p value Pearson’s r p value
Diabetes group −0.209 <0.001 −0.146 0.025
Control group −0.044 0.662 −0.279 0.002
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Loss of HAE may be related to HDL’s antioxidant func-
tion, which is also impaired by diabetes [24]. The HDL 
of diabetes patients are unable to reverse the inhibitory 
effect of oxidized LDL on endothelium-dependent vas-
orelaxation [25]. As a result, reductions in HAE-apoA-
I ratio may be due to the diabetes-associated enhanced 
inflammation.
Interestingly, there was little change in HAE during the 
5 years of follow-up for either diabetes patients or control 
subjects, both at the cohort and individual level. Delta 
values showed that for half of the cohort, the HDL func-
tion changed less than 15% over 5 years, with increases as 
common as decreases. Despite a lack of other supporting 
longitudinal studies, our data indicate that the effect of 
T1D on HDL function is rapid and persistent.
There was no gender difference in HDL function at 
baseline. At the 5-year follow-up, however, females had 
lower HDL function than males, both in the diabetes 
group and the control group. This difference was not 
explained by pubertal stage. We have previously dem-
onstrated gender differences in CRP levels in the ACD 
cohort, and these were largely accounted for by the pres-
ence of T1D and use of oral contraceptives [26]. The 
results of the present study indicate that HDL function is 
influenced by oral contraceptives in a similar manner, as 
there was no difference in HDL function between males 
and females without oral contraceptives. A large study 
of German adolescents has shown a correlation between 
oral contraceptives and an unfavorable CVD risk factor 
profile [27]. They found increased levels of both CRP and 
HDL in users of oral contraceptives, which is in line with 
a recent study of adult women [28]. HDL has both pro- 
and anti-inflammatory capabilities [29], and our results 
indicate that oral contraceptives may influence this prop-
erty of HDL. Consequently, reduced HDL function may 
contribute to the increased risk of CVD seen in females 
using oral contraceptives [30].
In previous studies of patients with T1D no association 
between HDL function and HbA1c were demonstrated, 
possibly due to small sample sizes [24, 25]. Similarly, 
correlations between HbA1c and HAE in the diabetes 
patients of this study were quite modest, and the asso-
ciation did not remain significant at follow-up when 
controlling for confounding variables. The significant 
association in the control group at follow-up is not eas-
ily explained, but might be clinically relevant. In a pre-
vious study of subjects without diabetes, elevated levels 
of HbA1c, though still within normal range, were sig-
nificantly associated with increased mortality risk [31]. 
Whether this increased risk is related to impaired HDL 
function requires further study.
CEC is inversely associated with cIMT and CVD events 
[11, 12]. Interestingly, despite the well-established cor-
relation between HAE and CEC, in the present study, 
there were no significant associations between HAE and 
our surrogate markers of atherosclerosis. This is probably 
due to the participants’ young age, the relatively short 
time since the onset of T1D, and the limited presence of 
Table 3 Linear multiple regression analyses
Significant associations between HAE-apoA-I ratio as the outcome variable and HbA1c as the explanatory variable
Patient selection Beta‑value R2 Standard error p value Variables controlled for
Diabetes group at baseline −0.707 0.094 0.262 0.007 Total cholesterol
Control group at follow‑up −5.508 0.078 1.703 0.002 None
Table 4 Predictive linear regression models with HAE-apoA-I ratio as the outcome variable
Patient selection R2 for the model Significant risk factors Beta‑value Standard error p 
value
Diabetes group at baseline 0.151 Insulin pump use −1.933 0.673 0.004
Total cholesterol −1.244 0.426 0.004
HDL cholesterol −2.479 0.823 0.003
HbA1c −0.923 0.285 0.001
Diabetes group at follow‑up 0.108 HDL cholesterol −3.031 0.764 <0.001
Smoking −5.282 1.970 0.008
HbA1c −0.502 0.259 0.054
Control group at baseline 0.104 HDL cholesterol −4.144 1.377 0.003
Smoking −11.715 5.827 0.047
Control group at follow‑up 0.176 HDL cholesterol −4.499 1.202 <0.001
HbA1c −4.768 1.655 0.005
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atherosclerosis in this age group. The previous studies 
demonstrating the relationship between CEC and CVD 
were composed of subjects (30–70 years of age) who had 
considerably more time to develop CVD than the sub-
jects of the current study [11–13].
The HAE-apoA-I ratio is a measure of HDL function per 
particle, analogous to measures of enzyme specific activ-
ity. The diabetes group exhibited elevated apoA-I levels. 
Interestingly, diabetes patients and controls exhibit similar 
HAE. This is likely due to the increase in apoA-I expres-
sion in T1D subjects, but whether this increase in apoA-I 
levels is a regulated compensatory mechanism is presently 
unknown. Elevated apoA-I in the diabetes group is prob-
ably not due to an anomalous selection in our cohort, as 
other studies show comparable differences [32, 33]. In the 
present study, HDL function per particle distinguished 
disease from healthy states better than the total level of 
HDL function, consistent with prior studies [18].
Inherent strengths of this study include the relatively 
large number of participants, the longitudinal design 
and the representative sample of diabetes patients as 
determined by comparison with the Norwegian Child-
hood Diabetes Registry. An innovative aspect of the 
study is the use of the HAE assay to quantify HDL 
function. The HAE assay requires only 50 µl of plasma, 
serum or whole blood and doesn’t require isolation of 
HDL. Instead, it directly assesses HDL function after a 
15-min incubation and 80-s read time in the EPR instru-
ment. The simplicity and minimal sample handling 
of the HAE assay contribute to its high precision (4% 
coefficient of variability) and day-to-day consistency 
(5% variability). The limitations of this study include 
the relatively narrow normal range of HAE response. 
The 75th percentile is approximately 30% greater than 
the 25th percentile. Abnormal and normal values may 
thus be difficult to distinguish. This result may be due 
to the relatively uniform genetic, social, age and lifestyle 
characteristics of the cohort. Another limitation is the 
lack of information about physical fitness and exercise 
in the cohort. Furthermore, BMI and waist circumfer-
ence were significantly higher in the diabetes group. 
Although these measures of body composition were not 
significant predictors of HDL function in our regression 
models, neither in the current nor in previous studies, 
the group disparity may have undetected influence on 
the results [21].
Conclusions
This study shows reduced HDL function, as measured 
by HAE-apoA-I ratio, in children and young adults with 
T1D compared with healthy control subjects. This dif-
ference was detectable early after the onset of T1D and 
persisted over the 5  years of the study, supporting the 
hypothesis that HDL function is compromised early and 
remains a chronic aspect of T1D. A persistent deficit in 
HDL function is likely a significant contributor to the 
enhanced CVD risk in these patients.
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